Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06603844 | First-in-human Study of CRB-601-01 to Treat Patients With Advanced Solid Tumor. | PHASE1/PHASE2 | RECRUITING | 156 | — | — | Dec 1, 2024 | Nov 1, 2026 | Jun 2, 2025 | - | — |
| Name | Type | Description |
|---|---|---|
| CRB-601 monoclonal antibody | DRUG | CRB-601 |
| Anti-PD-1 monoclonal antibody | DRUG | Anti-PD(L)-1 used as per label |
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab, V503, GARDASIL |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| AstraZeneca PLC | AZN | 1 | — | Trastuzumab deruxtecan |